Leading the data and digital team at Novartis, Bruno Villetelle believes that real world data should have a real world impact on patient care. He joins the #RealWorldTalk podcast to discuss how technology and data collection are being used at all stages of treatment to improve patients’ experiences and outcomes.
A recent observational study using real world data shows promising results from using tocilizumab in patients with severe COVID-19. According to study co-author Shivam Mathura, “While these results need to be further validated through clinical trials, we are thrilled to provide early insights to those in the field as we continue to fight this pandemic.”
COTA’s Chief Medical Officer, Dr. C.K. Wang spoke with BioCentury to help further the conversation around the role of RWD in increasing racial diversity in clinical research.
COTA is proud to share that we have joined a diverse group of 93 companies in signing an Amicus Brief to ratify the Equal Rights Amendment. By signing this Brief, COTA joins influential companies such as Apple, Biogen, Gilead Sciences and Pfizer, in demanding gender equality in the workplace and society at large.
Along with COTA’s data analytics expertise, Hackensack Meridian Health has been pioneering some of the early work to understand COVID-19. Stuart Goldberg, MD, chief of the Division of Outcomes and Value Research at the John Theurer Cancer Center and Mike Doyle, CEO of COTA, recently spoke with Health Evolution about the findings so far, and how we continue to learn from existing patients.
Around this growing interest and adoption, COTA’s chief medical officer, Dr. C.K. Wang, recently spoke with OncLive about how COTA’s Real World Analytics platform helps cancer centers correlate care patterns with outcomes.
In two recent articles, COTA CEO Mike Doyle reflects on how the pandemic is challenging leaders to be flexible and, specifically in healthcare, how data companies can be doing more.
To further explain COTA’s in-depth analysis and research methods from this ongoing work, Kathryn Tanenbaum, Senior Manager of Operations at COTA spoke with two of our data experts leading COTA’s analysis, Eric Hansen, director of analytics, and Shivam Mathura, director of product and strategy.
Leveraging its past knowledge of real-world evidence applications and learnings, COTA has joined the COVID-19 Evidence Accelerator program, a joint initiative of Friends of Cancer Research (Friends) and the Reagan-Udall Foundation for the Food and Drug Administration. Through this initiative, COTA is delivering findings from its observational, real-world studies using data from over 3,000 patients hospitalized with COVID-19 within the Hackensack Meridian Health network.
COTA, in collaboration with Hackensack Meridian Health and Berry Consultants, recently conducted a study using real-world data from more than 3,000 patients hospitalized with COVID-19. The study concluded hydroxychloroquine does not improve survival for patients hospitalized with COVID-19. It was also found that another drug, tocilizumab, may improve survival among critically ill intensive care unit patients.
Interested in learning more about how we can transform cancer care together?